LONG-TERM MANAGEMENT OF HYPERTENSION WITH PENTOLINIUM TARTRATE (ANSOLYSEN)

Publisher Website
Google Scholar
Abstract
The recent release of pentolinium tartrate (Ansolysen) to the medical profession prompts us to add our experience with this new and valuable agent to that already published1 in the hope that maximal clinical advantage can be taken of this powerful new drug. SERIES OF THIRTY-ONE PATIENTS Selection.— Only patients with one or more of the serious complications of hypertensive disease or with diastolic blood pressures consistently above 120 mm. Hg on repeated determinations were selected for long-term treatment. Ten of these 31 patients had previously had sympathectomy, since it is our belief that supradiaphragmatic sympathectomy still has a place in the treatment of rapidly progressive, severe hypertensive disease.2 No patients in whom therapy was instituted have been excluded from this study. Thus, the results to be described include our successes and failures indiscriminately. Determination of Dosage.— Since this was an attempt at long-continued management, we sought the maximal control